Examining Data for Osimertinib in EGFR+ Lung Cancer
Heather A. Wakelee, MD, discusses the use of osimertinib as a frontline treatment option for patients with <em>EGFR</em>-positive lung cancer.
Heather A. Wakelee, MD, an associate professor at Stanford University School of Medicine, discusses the use of osimertinib (Tagrisso) as a frontline treatment option for patients withEGFR-positive lung cancer.
In this patient population, there are several first- and second-generation options, according to Wakelee. Third-generation osimertinib was approved by the FDA for this population, as well, with supportive data directly comparing different tyrosine kinase inhibitors in the frontline.
Recent Videos
Overcoming Obstacles in Prescribing High-Cost Myeloma Therapies
Behind Durvalumab's FDA Approval: NIAGARA Trial in MIBC
Anti–LAG-3/Anti–PD-1 Combo Demonstrates Sustained Efficacy in Melanoma
Identifying Key Contributing Factors to the Oncology Workforce Shortage
Popat Covers Itacitinib and GVHD Prevention Trial Results
Pembrolizumab Combo Boosts Survival in HER2+ Gastric/GEJ Cancer
Insights on Offering BsAbs in a Community Setting Continued
Practical Insight for Administering BsAbs in A Community Setting
Behind the DeFi Trial: Nirogacestat for Patients With Desmoid Tumors
FDA Fully Approves Pembrolizumab/Trastuzumab Regimen in HER2+ Gastric Cancer
Related Content
